Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States


Autoři: Tyler N. A. Winkelman aff001;  Becky R. Ford aff002;  Rebecca J. Shlafer aff003;  Anna McWilliams aff002;  Lindsay K. Admon aff004;  Stephen W. Patrick aff005
Působiště autorů: Division of General Internal Medicine, Department of Medicine, Hennepin Healthcare, Minneapolis, Minnesota, United States of America aff001;  Health, Homelessness, and Criminal Justice Lab, Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States of America aff002;  Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America aff003;  Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, United States of America aff004;  Vanderbilt Center for Child Health Policy, Departments of Pediatrics and Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America aff005
Vyšlo v časopise: Medications for opioid use disorder among pregnant women referred by criminal justice agencies before and after Medicaid expansion: A retrospective study of admissions to treatment centers in the United States. PLoS Med 17(5): e32767. doi:10.1371/journal.pmed.1003119
Kategorie: Research Article
doi: 10.1371/journal.pmed.1003119

Souhrn

Background

Criminal justice involvement is common among pregnant women with opioid use disorder (OUD). Medications for OUD improve pregnancy-related outcomes, but trends in treatment data among justice-involved pregnant women are limited. We sought to examine trends in medications for OUD among pregnant women referred to treatment by criminal justice agencies and other sources before and after the Affordable Care Act’s Medicaid expansion.

Methods and findings

We conducted a serial, cross-sectional analysis using 1992–2017 data from pregnant women admitted to treatment facilities for OUD using a national survey of substance use treatment facilities in the United States (N = 131,838). We used multiple logistic regression and difference-in-differences methods to assess trends in medications for OUD by referral source. Women in the sample were predominantly aged 18–29 (63.3%), white non-Hispanic, high school graduates, and not employed. Over the study period, 26.3% (95% CI 25.7–27.0) of pregnant women referred by criminal justice agencies received medications for OUD, which was significantly less than those with individual referrals (adjusted rate ratio [ARR] 0.45, 95% CI 0.43–0.46; P < 0.001) or those referred from other sources (ARR 0.51, 95% CI 0.50–0.53; P < 0.001). Among pregnant women referred by criminal justice agencies, receipt of medications for OUD increased significantly more in states that expanded Medicaid (n = 32) compared with nonexpansion states (n = 18) (adjusted difference-in-differences: 12.0 percentage points, 95% CI 1.0–23.0; P = 0.03). Limitations of this study include encounters that are at treatment centers only and that do not encompass buprenorphine prescribed in ambulatory care settings, prisons, or jails.

Conclusions

Pregnant women with OUD referred by criminal justice agencies received evidence-based treatment at lower rates than women referred through other sources. Improving access to medications for OUD for pregnant women referred by criminal justice agencies could provide public health benefits to mothers, infants, and communities. Medicaid expansion is a potential mechanism for expanding access to evidence-based treatment for pregnant women in the US.

Klíčová slova:

Census – Criminal justice system – Drug therapy – Management of high-risk pregnancies – Morbidity – Obstetrics and gynecology – Opioids – Pregnancy


Zdroje

1. VanHouten JP, Rudd RA, Ballesteros MF, Mack KA. Drug overdose deaths among women aged 30–64 years—United States, 1999–2017. MMWR Morb Mortal Wkly Rep. 2019;68: 1–5. doi: 10.15585/mmwr.mm6801a1 30629574

2. Admon LK, Bart G, Kozhimannil KB, Richardson CR, Dalton VK, Winkelman TNA. Amphetamine- and Opioid-Affected Births: Incidence, Outcomes, and Costs, United States, 2004–2015. Am J Public Health. 2019;109: 148–154. doi: 10.2105/AJPH.2018.304771 30496001

3. Haight SC, Ko JY, Tong VT, Bohm MK, Callaghan WM. Opioid Use Disorder Documented at Delivery Hospitalization—United States, 1999–2014. MMWR Morb Mortal Wkly Rep. 2018;67: 845–849. doi: 10.15585/mmwr.mm6731a1 30091969

4. Jones Hendrée E., O’Grady Kevin E., Malfi Debbie, Tuten Michelle. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict. 2010;17: 372–386. doi: 10.1080/10550490802266276 18770079

5. Committee on Obstetric Practice. Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. American College of Obstetricians and Gyncecologists. Obstet Gynecol. 2017;130: e81–94. doi: 10.1097/AOG.0000000000002235 28742676

6. Terplan M, Laird HJ, Hand DJ, Wright TE, Premkumar A, Martin CE, et al. Opioid detoxification during pregnancy: a systematic review. Obstet Gynecol. 2018;131: 803–814. doi: 10.1097/AOG.0000000000002562 29630016

7. Short VL, Hand DJ, MacAfee L, Abatemarco DJ, Terplan M. Trends and disparities in receipt of pharmacotherapy among pregnant women in publically funded treatment programs for opioid use disorder in the United States. J Subst Abuse Treat. 2018;89: 67–74. doi: 10.1016/j.jsat.2018.04.003 29706175

8. Martin CE, Longinaker N, Terplan M. Recent trends in treatment admissions for prescription opioid abuse during pregnancy. J Subst Abuse Treat. 2015;48: 37–42. doi: 10.1016/j.jsat.2014.07.007 25151440

9. The Sentencing Project. Incarcerated Women and Girls. Washington, DC: The Sentencing Project; 2019 Jun [cited 2020 Apr 20]. Available from: https://www.sentencingproject.org/publications/incarcerated-women-and-girls/.

10. Sufrin C. Jailcare—finding the safety net for women behind bars. Oakland, CA: University of California Press; 2017.

11. Csete J. Criminal justice barriers to treatment of opioid use disorders in the United States: the need for public health advocacy. Am J Public Health. 2019;109: 419–422. doi: 10.2105/AJPH.2018.304852 30676805

12. Krawczyk N, Picher CE, Feder KA, Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff (Millwood). 2017;36: 2046–2053. doi: 10.1377/hlthaff.2017.0890 29200340

13. Binswanger IA. Mortality After Prison Release: Opioid Overdose and Other Causes of Death, Risk Factors, and Time Trends From 1999 to 2009. Ann Intern Med. 2013;159: 592. doi: 10.7326/0003-4819-159-9-201311050-00005 24189594

14. Winkelman TNA, Kieffer EC, Goold SD, Morenoff JD, Cross K, Ayanian JZ. Health insurance trends and access to behavioral healthcare among justice-involved individuals—United States, 2008–2014. J Gen Intern Med. 2016;31: 1523–1529. doi: 10.1007/s11606-016-3845-5 27638837

15. Knapp CD, Howell BA, Wang EA, Shlafer RJ, Hardeman RR, Winkelman TNA. Health insurance gains after implementation of the Affordable Care Act among individuals recently on probation: USA, 2008–2016. J Gen Intern Med. 2019. doi: 10.1007/s11606-019-04900-3 30815787

16. Saloner B, Levin J, Chang H-Y, Jones C, Alexander GC. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act medicaid expansion. JAMA Netw Open. 2018;1: e181588. doi: 10.1001/jamanetworkopen.2018.1588 30646116

17. Bandara SN, Huskamp HA, Riedel LE, McGinty EE, Webster D, Toone RE, et al. Leveraging the Affordable Care Act to enroll justice-involved populations in Medicaid: state and local efforts. Health Aff (Millwood). 2015;34: 2044–2051. doi: 10.1377/hlthaff.2015.0668 26643624

18. Somers SA, Nicolella E, Hamblin A, McMahon SM, Heiss C, Brockmann BW. Medicaid expansion: considerations for states regarding newly eligible jail-involved individuals. Health Aff (Millwood). 2014;33: 455–461. doi: 10.1377/hlthaff.2013.1132 24590945

19. Meinhofer A, Witman AE. The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion. J Health Econ. 2018;60: 177–197. doi: 10.1016/j.jhealeco.2018.06.004 29990675

20. Substance Abuse and Mental Health Services Administration (SAMHSA). In: Treatment episode data set (TEDS) 1992–2017 [Internet]. [cited 2020 Apr 20]. Available from: https://www.datafiles.samhsa.gov/study-series/treatment-episode-data-set-admissions-teds-nid13518.

21. Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M. The Affordable Care Act and opioid agonist therapy for opioid use disorder. Psychiatr Serv. 2019;70: 617–620. doi: 10.1176/appi.ps.201900025 31035894

22. Sommers BD, Gunja MZ, Finegold K, Musco T. Changes in self-reported insurance coverage, access to care, and health under the Affordable Care Act. JAMA. 2015;314: 366–374. doi: 10.1001/jama.2015.8421 26219054

23. Sommers BD, Blendon RJ, Orav EJ, Epstein AM. Changes in utilization and health among low-income adults after Medicaid expansion or expanded private insurance. JAMA Intern Med. 2016;176: 1501–1509. doi: 10.1001/jamainternmed.2016.4419 27532694

24. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65: 146–157. doi: 10.1176/appi.ps.201300235 24248468

25. Peeler M, Fiscella K, Terplan M, Sufrin C. Best practices for pregnant incarcerated women with opioid use disorder. J Correct Health Care. 2019; 107834581881985. doi: 10.1177/1078345818819855 30616487

26. Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, et al. Medication assisted treatment in US drug courts: Results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44: 473–480. doi: 10.1016/j.jsat.2012.10.004 23217610

27. Sufrin C, Sutherland L, Beal L, Terplan M, Latkin C, Clarke JG. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study. Addict Abingdon Engl. 2020. doi: 10.1111/add.15030 32141128

28. Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a Cascade of Care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45: 1–10. doi: 10.1080/00952990.2018.1546862 30675818

29. Bonfine N, Munetz MR, Simera RH. Sequential intercept mapping: developing systems-level solutions for the opioid epidemic. Psychiatr Serv. 2018;69: 1124–1126. doi: 10.1176/appi.ps.201800192 30185122

30. Patrick SW, Schiff DM, Prevention C on SUA. A public health response to opioid use in pregnancy. Pediatrics. 2017; e20164070. doi: 10.1542/peds.2016-4070 28219965

31. Kozhimannil KB, Dowd WN, Ali MM, Novak P, Chen J. Substance use disorder treatment admissions and state-level prenatal substance use policies: evidence from a national treatment database. Addict Behav. 2019;90: 272–277. doi: 10.1016/j.addbeh.2018.11.019 30472535

32. Daw JR, Sommers BD. Association of the Affordable Care Act dependent coverage provision with prenatal care use and birth outcomes. JAMA. 2018;319: 579. doi: 10.1001/jama.2018.0030 29450525

33. Daw JR, Sommers BD. The Affordable Care Act and access to care for reproductive-aged and pregnant women in the United States, 2010–2016. Am J Public Health. 2019;109: 565–571. doi: 10.2105/AJPH.2018.304928 30789761

34. Daw JR, Hatfield LA, Swartz K, Sommers BD. Women in the United States experience high rates of coverage ‘churn’ in months before and after childbirth. Health Aff (Millwood). 2017;36: 598–606. doi: 10.1377/hlthaff.2016.1241 28373324

35. Olfson M, Wall M, Barry CL, Mauro C, Mojtabai R. Impact of medicaid expansion on coverage and treatment of low-income adults with substance use disorders. Health Aff (Millwood). 2018;37: 1208–1215. doi: 10.1377/hlthaff.2018.0124 30080455

36. Saloner B, Stoller KB, Barry CL. Medicaid coverage for methadone maintenance and use of opioid agonist therapy in specialty addiction treatment. Psychiatr Serv. 2016;67: 676–679. doi: 10.1176/appi.ps.201500228 26927578

37. Treatment Episode Data Set Admissions (TEDS-A), 2014—Codebook. Rockville, MD: Center for Behavioral Health Statistics and Quality. Substance Abuse and Mental Health Services Administration; [cited 2020 Apr 20]. Available from: https://www.datafiles.samhsa.gov/study-dataset/treatment-episode-data-set-admissions-2014-teds-2014-ds0001-nid16950.

38. Wen H, Borders TF, Cummings JR. Trends in buprenorphine prescribing by physician specialty. Health Aff (Millwood). 2019;38: 24–28. doi: 10.1377/hlthaff.2018.05145 30615523

Štítky
Interní lékařství

Článek vyšel v časopise

PLOS Medicine


2020 Číslo 5

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Kurz originály vs. generika
nový kurz
Autoři:

Klinická farmakokinetika betablokátorů
Autoři:

Současné možnosti terapie osteoartrózy
Autoři: MUDr. Jakub Holešovský

Preferovaná úlevová léčba Asthma Bronchiale
Autoři: PharmDr. Petr Sedlák

Inhibitory karboanhydrázy v léčbě glaukomu
Autoři: MUDr. Petr Výborný, CSc., FEBO

Všechny kurzy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se